Nanoparticle-Based Cancer Therapy: Advances, Mechanisms, and Clinical Translation

Abstract

Cancer remains a leading cause of mortality worldwide, driven by complex pathophysiology and resistance to conventional therapies. Nanoparticles (1–100 nm) offer a transformative platform, combining biocompatibility, reduced toxicity, enhanced stability, and precise tumor targeting through the enhanced permeability and retention (EPR) effect. This review surveys nanoparticle classifications, targeting strategies, approved nanomedicines, and the challenges hindering clinical translation. We highlight recent breakthroughs in overcoming multidrug resistance (MDR) and discuss future directions for integrating nanotechnology into standard oncology practice.

Introduction

Cancer arises from uncontrolled cell proliferation, fueled by genetic mutations and environmental factors. Traditional modalities—surgery, chemotherapy, radiation, targeted therapy, immunotherapy—often suffer from limited specificity, systemic toxicity, and drug resistance. Nanotechnology introduces engineered carriers that can encapsulate therapeutics, protect them from degradation, and deliver them selectively to tumor tissues, thereby enhancing efficacy and minimizing adverse effects.

Nanoparticles: Definition and Classification

Nanoparticles are sub‑100‑nm structures with unique physicochemical properties. They are categorized by shape (0D, 1D, 2D, 3D) and composition (organic, inorganic, hybrid). Key attributes—size, surface chemistry, charge—dictate biodistribution, cellular uptake, and drug release kinetics.

Fabrication Strategies

Two main approaches:

• Bottom‑up: Molecular self‑assembly, sol‑gel, chemical vapor deposition, biosynthesis.
• Top‑down: Mechanical milling, lithography, laser ablation, etching.

Cellular Targeting Mechanisms

Targeting strategies fall into two categories:

• Passive targeting: Exploits tumor vasculature leakiness and impaired lymphatics (EPR effect). Nanoparticles (10–100 nm) accumulate in tumor interstitium and release drugs in the acidic microenvironment.
• Active targeting: Ligand-mediated binding to overexpressed receptors (e.g., transferrin, folate, EGFR). Surface functionalization enhances cellular uptake via receptor‑mediated endocytosis.

Nanoparticle Platforms in Oncology

• Polymeric NPs: Biodegradable matrices (PLGA, PLA, chitosan) enable controlled release and reduced toxicity.
• Dendrimers: Hyperbranched polymers (PAMAM, PPI) provide multivalent surface for drug loading and gene delivery.
• Monoclonal antibody conjugates: Antibody–drug nanoparticles (ADCs) combine targeting specificity with potent cytotoxins.
• Extracellular vesicles: Exosome‑based carriers inherit natural tropism and evade immune clearance.
• Liposomes: Phospholipid bilayers encapsulate hydrophilic/hydrophobic drugs; clinically approved examples include Doxil® and Abraxane®.
• Solid lipid nanoparticles (SLNs) & nanoemulsions: Lipid core structures enhance drug solubility and stability.
• Cyclodextrin nanosponges: Macromolecular hosts improve loading and release of hydrophobic drugs.

Inorganic Nanoparticles

• Carbon-based: Graphene, fullerenes, carbon nanotubes—offer high surface area, photothermal and imaging capabilities.
• Quantum dots: Semiconductor nanocrystals for imaging and targeted therapy.
• Metallic NPs: Gold, silver, iron oxide—used for imaging, hyperthermia, and drug delivery.
• Magnetic NPs: Superparamagnetic iron oxide nanoparticles enable MRI contrast and magnetic hyperthermia.
• Calcium phosphate & silica NPs: Biodegradable carriers for gene delivery and drug loading.

Overcoming Drug Resistance

Nanoparticles address MDR via:

• Efflux transporter inhibition: Co‑encapsulation of chemotherapeutics with P‑gp inhibitors or siRNA targeting efflux pumps.
• Apoptosis modulation: Delivery of Bcl‑2 siRNA, NF‑κB inhibitors, or pro‑apoptotic agents (e.g., ceramide) to restore cell death pathways.
• Hypoxia targeting: HIF‑1α siRNA or PI3K/Akt/mTOR inhibitors delivered by nanoparticles to sensitize hypoxic tumor cells.

Nanoparticles in Immunotherapy

NPs enhance immunotherapeutic strategies by:

• Delivering tumor‑associated antigens and adjuvants to dendritic cells (nanovaccines).
• Engineering artificial antigen‑presenting cells (aAPCs) for T‑cell activation.
• Targeting immunosuppressive tumor microenvironment (TAMs, MDSCs) to remodel immune contexture.
• Co‑delivering checkpoint inhibitors with nanoparticles to improve tumor penetration and reduce systemic toxicity.

Other Emerging Applications

• Cryosurgery: Nanoparticles with high thermal conductivity enhance localized freezing, while phase‑change materials protect adjacent tissues.

Clinical Translation Challenges

• Biological barriers: Limited biodistribution, protein corona formation, and off‑target uptake by mononuclear phagocyte system.
• Toxicity concerns: Size‑dependent pulmonary, hepatic, and renal effects; oxidative stress induced by certain metal NPs.
• Manufacturing scale‑up: Reproducible synthesis, batch consistency, and regulatory compliance.
• Clinical study design: Adequate animal models, patient selection, and endpoints that reflect translational relevance.

Conclusion and Outlook

Nanoparticle‑based drug delivery has matured from bench to bedside, offering improved pharmacokinetics, tumor specificity, and the ability to overcome MDR. Continued interdisciplinary research—integrating proteomics, genomics, and advanced modeling—will refine NP design, mitigate safety concerns, and accelerate the transition of nanomedicines into routine oncology practice.

Availability of Data and Materials

Not applicable.